Related Experiment Video
Updated: Jun 7, 2026
06:32
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Global histone modification patterns as prognostic markers to classify glioma patients
Bo-lin Liu1, Jin-xiang Cheng, Xiang Zhang
1Department of Neurosurgery, Xijing Institute of Clinical Neuroscience, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, People's Republic of China.
Summary
Epigenetic changes in histone modifications can predict glioma patient prognosis. Histone modifications, combined with clinical factors, identified distinct prognostic groups impacting survival.
Area of Science:
- Neuro-oncology
- Epigenetics
- Cancer Biomarkers
Background:
- Altered epigenetic modifications are crucial in tumor development and progression.
- Histone modifications play a significant role in various cancers, including glioma.
Purpose of the Study:
- To investigate epigenetic changes involving multiple histone modifications.
- To predict the prognosis of glioma patients based on histone modification patterns.
Main Methods:
- Immunohistochemistry was used to assess global histone modification expression in 230 glioma tumor samples.
- Specific modifications analyzed include H3K4diMe, H4R3monoMe, H4K20triMe, H3K9Ac, H3K18Ac, H4K12Ac, and H4K16Ac.
- Recursive partitioning analysis (RPA) was employed for data analysis.
Main Results:
- RPA identified 10 distinct prognostic groups based on WHO grade, histology, and specific histone modifications (H3K9Ac, H3K4diMe, H3K18Ac, H4K20triMe).
- These groups showed significantly different progression-free and overall survival rates (P < 0.0001).
- RPA grouping and age were independent predictors of overall survival, while RPA grouping was the sole independent predictor for progression-free survival.
Conclusions:
- Multiple histone modifications demonstrate prognostic relevance in glioma.
- Further research is warranted to evaluate histone modifications as predictive markers for treatment response, particularly with histone deacetylase inhibitors.
